Immutep Limited (PRRUF)
USD 0.2
(-26.74%)
USD 0.2
(-26.74%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -44.54 Million AUD | -12.57% |
| 2023 | -39.57 Million AUD | -34.51% |
| 2022 | -31.87 Million AUD | -53.81% |
| 2021 | -20.72 Million AUD | -48.66% |
| 2020 | -13.45 Million AUD | 24.81% |
| 2019 | -18.34 Million AUD | -76.37% |
| 2018 | -10.93 Million AUD | -25.08% |
| 2017 | -8.4 Million AUD | 86.14% |
| 2016 | -61.19 Million AUD | -362.09% |
| 2015 | -13.12 Million AUD | 8.95% |
| 2014 | -14.4 Million AUD | 22.49% |
| 2013 | -18.59 Million AUD | -2.86% |
| 2012 | -18.07 Million AUD | -28.5% |
| 2011 | -14.06 Million AUD | -79.97% |
| 2010 | -10.96 Million AUD | -348.38% |
| 2009 | -2.74 Million AUD | 6.83% |
| 2008 | -1.87 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -24.24 Million AUD | 0.0% |
| 2024 Q4 | -22.34 Million AUD | 0.0% |
| 2024 FY | - AUD | -12.27% |
| 2023 Q4 | -20.9 Million AUD | 0.0% |
| 2023 FY | - AUD | -34.51% |
| 2023 Q2 | -22.17 Million AUD | 0.0% |
| 2022 FY | - AUD | -53.81% |
| 2022 Q2 | -17.97 Million AUD | 0.0% |
| 2022 Q4 | -18.33 Million AUD | 0.0% |
| 2021 FY | - AUD | -48.66% |
| 2021 Q2 | -11.55 Million AUD | 0.0% |
| 2021 Q4 | -9.89 Million AUD | 0.0% |
| 2020 FY | - AUD | 24.81% |
| 2020 Q2 | -7.62 Million AUD | 0.0% |
| 2020 Q4 | -11.62 Million AUD | 0.0% |
| 2019 Q4 | -11.98 Million AUD | 0.0% |
| 2019 FY | - AUD | -76.37% |
| 2019 Q2 | -8.55 Million AUD | 0.0% |
| 2018 Q2 | -4.4 Million AUD | 0.0% |
| 2018 FY | - AUD | -25.08% |
| 2018 Q4 | -5.97 Million AUD | 0.0% |
| 2017 Q4 | -3.31 Million AUD | -115.2% |
| 2017 FY | - AUD | 86.14% |
| 2017 Q3 | -1.54 Million AUD | 52.38% |
| 2017 Q2 | -3.23 Million AUD | 0.0% |
| 2016 Q2 | -54.39 Million AUD | 0.0% |
| 2016 FY | - AUD | -362.09% |
| 2016 Q4 | -3.28 Million AUD | -43.71% |
| 2016 Q3 | -2.28 Million AUD | 95.79% |
| 2015 FY | - AUD | 8.95% |
| 2015 Q4 | -6.58 Million AUD | 0.0% |
| 2015 Q2 | -6.75 Million AUD | 0.0% |
| 2014 FY | - AUD | 22.49% |
| 2014 Q4 | -7.41 Million AUD | 0.0% |
| 2014 Q2 | -6.58 Million AUD | 0.0% |
| 2013 Q4 | -9.04 Million AUD | 0.0% |
| 2013 FY | - AUD | -2.86% |
| 2013 Q2 | -8.16 Million AUD | 0.0% |
| 2012 FY | - AUD | -28.5% |
| 2011 FY | - AUD | -79.97% |
| 2010 FY | - AUD | -348.38% |
| 2009 FY | - AUD | 6.83% |
| 2008 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1354.265% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1155.833% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1849.861% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -156.444% |
| GB Sciences, Inc. | -1.41 Million USD | -3037.181% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 11857.971% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -364151.926% |
| Skye Bioscience, Inc. | -13.54 Million USD | -228.8% |
| Zenith Capital Corp. | -8.6 Million USD | -417.597% |
| Agentix Corp. | -1.37 Million USD | -3147.252% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1046.774% |
| Biomind Labs Inc. | -1.03 Million USD | -4205.68% |
| ContraFect Corporation | -64.99 Million USD | 31.469% |
| CSL Limited | 4.78 Billion USD | 100.93% |
| CytoDyn Inc. | -18.02 Million USD | -147.071% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 662568.293% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -6943.635% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 19.506% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -12030.125% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2799.931% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -4654.193% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 147.368% |
| SQZ Biotechnologies Company | -64.14 Million USD | 30.552% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -2894.757% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 37.293% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1584.449% |
| Mesoblast Limited | -62.38 Million USD | 28.603% |
| Marizyme, Inc. | -34.28 Million USD | -29.937% |
| Genus plc | 73.7 Million USD | 160.44% |
| Pharming Group N.V. | 9.87 Million USD | 550.991% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -407.802% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -3077.637% |
| IMV Inc. | -35.52 Million USD | -25.394% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1816.86% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -8498.535% |
| ONE Bio Corp. | 13.61 Million USD | 427.218% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 7.636% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1347.043% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1440.088% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -522.017% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -178077.472% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -180.687% |
| Alpha Cognition Inc. | -9.7 Million USD | -358.955% |
| Enzolytics Inc. | -2.12 Million USD | -1999.14% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 79.38% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 3760.178% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 603.11% |
| Genscript Biotech Corporation | -248.71 Million USD | 82.091% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -651.308% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -18526.121% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1720.768% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -25205.797% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2218.919% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -573.739% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -884.146% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -1088.985% |
| Helix BioMedix, Inc. | -1.04 Million USD | -4157.274% |
| EV Biologics, Inc. | -1.26 Million USD | -3415.369% |
| Q BioMed Inc. | -617.62 Thousand USD | -7112.168% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -2445.394% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -12.381% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -489.707% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1680.377% |
| HST Global, Inc. | -5303.00 USD | -839884.311% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2065.502% |
| Halberd Corporation | -74.27 Thousand USD | -59868.993% |
| Resverlogix Corp. | -11.74 Million USD | -279.359% |
| Cell Source, Inc. | -4.27 Million USD | -942.577% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2871.792% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -628.725% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -255593.519% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -4204.648% |
| Kadimastem Ltd | -2.62 Million USD | -1597.329% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -11633.936% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -24498.189% |
| LadRx Corporation | 412.28 Thousand USD | 10904.318% |
| Regen BioPharma, Inc. | 1.46 Million USD | 3138.588% |
| Affymax, Inc. | -14.29 Million USD | -211.608% |
| Itoco Inc. | -1.86 Million USD | -2283.333% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3891.431% |
| Mobile Lads Corp. | -2.24 Million USD | -1887.559% |
| International Stem Cell Corporation | 202 Thousand USD | 22151.667% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -1066.038% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -56264.585% |
| Qrons Inc. | -40.08 Thousand USD | -111035.87% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -9071.584% |
| SYBLEU INC | -141.57 Thousand USD | -31364.331% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 8545.503% |
| Rebus Holdings, Inc. | -951 Thousand USD | -4583.95% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -4094.345% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -84520.76% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1709.326% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -24.186% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -98887.484% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1526.894% |
| Neutra Corp. | -181.24 Thousand USD | -24476.61% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -120.965% |
| PureTech Health plc | -11.62 Million USD | -283.111% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -120.98% |
| IXICO plc | -707 Thousand USD | -6200.476% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -479.627% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 7.863% |
| CSL Limited | 4.73 Billion USD | 100.941% |
| Cellectis S.A. | -92.63 Million USD | 51.915% |